| BMD < −1SD | Fracture | ||
---|---|---|---|---|
 | OR [95% CI] | P | OR [95% CI] | P |
Menopause | 5.29 [1.83; 15.27] | 0.002 | 2.1 [0.68; 6.53] | 0.2 |
Age, years | 1.06 [1.03; 1.1] | <0.001 | 1.09 [1.05; 1.14] | <0.001 |
Calcium intake <500Â mg/d | 4.28 [1.89; 9.72] | <0.001 | 2.2 [0.93; 5.18] | 0.072 |
Stage NHYA 3 or 4 | 3.34 [1.3; 8.54] | 0.012 | 3.18 [1.23; 8.2] | 0.017 |
Disease duration | 1.05 [1; 1.1] | 0.047 | 1 [0.95; 1.06] | 0.9 |
Cumulative CS dose | 1.15 [0.98; 1.36] | 0.088 | 1.2 [0.99; 1.44] | 0.059 |
Current CS treatment | 1.68 [0.83; 3.4] | 0.15 | 2.63 [1.08; 6.37] | 0.033 |
Vitamin D supplements | 3.82 [1.66; 8.8] | 0.002 | 2.07 [0.87; 4.95] | 0.1 |
BP treatment | 3.03 [1.44; 6.36] | 0.003 | 1.83 [0.8; 4.15] | 0.15 |
ESR >10Â mm/h | 2.49 [1.1; 5.62] | 0.028 | 1.38 [0.55; 3.46 | 0.5 |
Lymphocytes >1,000/mm3 | 0.45 [0.21; 0.94] | 0.033 | 1.19 [0.5; 2.85] | 0.7 |
Creatinine clearance, ml/mn | 0.99 [0.98; 1] | 0.034 | 0.97 [0.95; 0.99] | <0.001 |
25(OH)D serum level | Â | Â | Â | Â |
25(OH)D ≤10 ng/ml | 1 | - | 1 | - |
10 < 25(OH)D <20 ng/ml | 0.48 [0.21; 1.09] | 0.079 | 1.24 [0.45; 8.23] | 0.67 |
25(OH)D >20Â ng/ml | 2.00 [0.8; 4.97] | 0.13 | 2.94 [1.05; 8.23] | 0.04 |
Serum PTH level, pmol/l | Â | Â | Â | Â |
Fracture/low BMD | 4.39 [1.86; 10.37] | <0.001 | 4.39 [1.86; 10.37] | <0.001 |